Due to a system-wide technology update, we are experiencing extremely high call volume. We appreciate your patience with our operators during this time. Thank you for choosing Fox Chase Cancer Center.
International Collaboration Facilitates Fox Chase Researcher's Study on Partial Nephrectomy Resection Technique
PHILADELPHIA (April 15, 2020) – A study on partial nephrectomy techniques by Alexander Kutikov, MD, FACS, chief of the Division of Urology and Urologic Oncology at Fox Chase Cancer Center and a member of the Molecular Therapeutics Program, was recently published after years of collaboration involving centers in the United States and Europe.
The study examined how the resection technique used during partial nephrectomy might affect operative outcomes and surgical margins. While this study is new, this collaborative approach to nephrectomy dates back many years, Kutikov said.
Kutikov collaborated with Andrea Minervini, MD, an associate professor of Urology at the University of Florence, Italy, over several years in pursuit of optimal surgical strategies for kidney cancer. Kutikov met Minervini, the study’s lead author, while traveling in Europe and the two struck up a friendship.
“We talked about how different centers in the United States, Europe, and around the world approached surgical approaches to kidney tumors a little differently, and how everybody thought their approach was the best approach,” Kutikov said. “We decided that instead of arguing about which way was better, we should figure out how to better identify and standardize reporting and then compare results.”
As one of their first projects, Kutikov and Minervini worked with their teams to develop the Surface-Intermediate-Base (SIB) Margin Score, which attempts to standardize reporting of nephron-sparing surgery resection techniques. These techniques are typically defined as enucleation, enucleoresection, and resection.
To get an SIB score, the surgeon does a visual analysis of the renal mass after partial nephrectomy and assigns a score while in the operating room. This score has been validated and shown to correctly discriminate among different resection techniques.
“We were able to show that what the surgeon documented in the OR by observation with the naked eye correlated with what the pathologist saw under the microscope,” Kutikov said. Because of that, the study allows other studies to be conducted using these standardized scores to compare outcomes across centers.
“This is the first time we are able to standardize reporting across the world, help surgeons understand what they are actually doing, and compare results,” Kutikov said.
For example, some centers report that they try to avoid enucleation, but these studies have shown that upon closer inspection, enucleation may occur inadvertently. “Now that we have started documenting what we are doing, our results can become more meaningful,” Kutikov said. “We hope to continue to collaborate across the Atlantic to improve cancer care together.”
The study, “Impact of Resection Technique on Perioperative Outcomes and Surgical Margins after Partial Nephrectomy for Localized Renal Masses: A Prospective Multicenter Study,” was published in The Journal of Urology, published by Wolters Kluwer.
Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence five consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.
For more information, call 888-369-2427